Identification of cisplatin sensitizers through high-throughput combinatorial screening

Yichen Sun, Weiye Jiang, Wenhua Lu, Ming Song, Kaiyan Liu, Ping Chen, Allison Chang, Jianhua Ling, Paul J. Chiao, Yumin Hu, Peng Huang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

cis-Diamminedichloroplatinum/cisplatin (CDDP) is a major drug used in cancer chemotherapy; however, the toxic side-effects and development of drug resistance represent major challenges to the clinical use of CDDP. The aim of the present study was to identify effective drug combination regimens through high-throughput drug screening that can enhance the efficacy of CDDP, and to investigate the underlying mechanisms. A cell-based high-throughput screening methodology was implemented, using a library of 1,280 Food and Drug Administration (FDA)-approved drugs, to identify clinical compounds that act synergistically with CDDP. Our study identified two compounds, namely potassium antimony tartrate and topotecan, that significantly enhanced the sensitivity of colorectal and non-small cell lung cancer cells to CDDP. The synergistic action of both compounds with CDDP was confirmed by further quantitative analyses. Topotecan is a topoisomerase-1 inhibitor that has previously been shown to enhance the clinical response and overall patient survival when combined with CDDP by a yet unclear mechanism. We demonstrated that the combination of topotecan with CDDP significantly inhibited colony formation ability and increased the apoptosis of several cancer cell lines. Mechanistic analyses revealed that topotecan enhanced CDDP-induced DNA damage and inhibited the repair of DNA strand breaks, without affecting the cellular platinum content. Overall, the findings of this study demonstrated that the use of the FDA-approved drug panel in high-throughput screening is an effective method for identifying effective therapeutic regimens that are clinically relevant, and may have high feasibility for translation into clinical practice.

Original languageEnglish (US)
Pages (from-to)1237-1246
Number of pages10
JournalInternational journal of oncology
Volume53
Issue number3
DOIs
StatePublished - Sep 2018

Fingerprint

Cisplatin
Topotecan
United States Food and Drug Administration
Antimony Potassium Tartrate
Pharmaceutical Preparations
Topoisomerase I Inhibitors
Preclinical Drug Evaluations
DNA Breaks
Poisons
Drug Combinations
Platinum
Drug-Related Side Effects and Adverse Reactions
Drug Resistance
Non-Small Cell Lung Carcinoma
DNA Damage
Libraries
Neoplasms

Keywords

  • Cisplatin
  • DNA damage
  • Drug combination
  • High-throughput screening
  • PAT
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Identification of cisplatin sensitizers through high-throughput combinatorial screening. / Sun, Yichen; Jiang, Weiye; Lu, Wenhua; Song, Ming; Liu, Kaiyan; Chen, Ping; Chang, Allison; Ling, Jianhua; Chiao, Paul J.; Hu, Yumin; Huang, Peng.

In: International journal of oncology, Vol. 53, No. 3, 09.2018, p. 1237-1246.

Research output: Contribution to journalArticle

Sun, Yichen ; Jiang, Weiye ; Lu, Wenhua ; Song, Ming ; Liu, Kaiyan ; Chen, Ping ; Chang, Allison ; Ling, Jianhua ; Chiao, Paul J. ; Hu, Yumin ; Huang, Peng. / Identification of cisplatin sensitizers through high-throughput combinatorial screening. In: International journal of oncology. 2018 ; Vol. 53, No. 3. pp. 1237-1246.
@article{cdea48a3abdd4ef2be908c5ad20b575b,
title = "Identification of cisplatin sensitizers through high-throughput combinatorial screening",
abstract = "cis-Diamminedichloroplatinum/cisplatin (CDDP) is a major drug used in cancer chemotherapy; however, the toxic side-effects and development of drug resistance represent major challenges to the clinical use of CDDP. The aim of the present study was to identify effective drug combination regimens through high-throughput drug screening that can enhance the efficacy of CDDP, and to investigate the underlying mechanisms. A cell-based high-throughput screening methodology was implemented, using a library of 1,280 Food and Drug Administration (FDA)-approved drugs, to identify clinical compounds that act synergistically with CDDP. Our study identified two compounds, namely potassium antimony tartrate and topotecan, that significantly enhanced the sensitivity of colorectal and non-small cell lung cancer cells to CDDP. The synergistic action of both compounds with CDDP was confirmed by further quantitative analyses. Topotecan is a topoisomerase-1 inhibitor that has previously been shown to enhance the clinical response and overall patient survival when combined with CDDP by a yet unclear mechanism. We demonstrated that the combination of topotecan with CDDP significantly inhibited colony formation ability and increased the apoptosis of several cancer cell lines. Mechanistic analyses revealed that topotecan enhanced CDDP-induced DNA damage and inhibited the repair of DNA strand breaks, without affecting the cellular platinum content. Overall, the findings of this study demonstrated that the use of the FDA-approved drug panel in high-throughput screening is an effective method for identifying effective therapeutic regimens that are clinically relevant, and may have high feasibility for translation into clinical practice.",
keywords = "Cisplatin, DNA damage, Drug combination, High-throughput screening, PAT, Topotecan",
author = "Yichen Sun and Weiye Jiang and Wenhua Lu and Ming Song and Kaiyan Liu and Ping Chen and Allison Chang and Jianhua Ling and Chiao, {Paul J.} and Yumin Hu and Peng Huang",
year = "2018",
month = "9",
doi = "10.3892/ijo.2018.4447",
language = "English (US)",
volume = "53",
pages = "1237--1246",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Identification of cisplatin sensitizers through high-throughput combinatorial screening

AU - Sun, Yichen

AU - Jiang, Weiye

AU - Lu, Wenhua

AU - Song, Ming

AU - Liu, Kaiyan

AU - Chen, Ping

AU - Chang, Allison

AU - Ling, Jianhua

AU - Chiao, Paul J.

AU - Hu, Yumin

AU - Huang, Peng

PY - 2018/9

Y1 - 2018/9

N2 - cis-Diamminedichloroplatinum/cisplatin (CDDP) is a major drug used in cancer chemotherapy; however, the toxic side-effects and development of drug resistance represent major challenges to the clinical use of CDDP. The aim of the present study was to identify effective drug combination regimens through high-throughput drug screening that can enhance the efficacy of CDDP, and to investigate the underlying mechanisms. A cell-based high-throughput screening methodology was implemented, using a library of 1,280 Food and Drug Administration (FDA)-approved drugs, to identify clinical compounds that act synergistically with CDDP. Our study identified two compounds, namely potassium antimony tartrate and topotecan, that significantly enhanced the sensitivity of colorectal and non-small cell lung cancer cells to CDDP. The synergistic action of both compounds with CDDP was confirmed by further quantitative analyses. Topotecan is a topoisomerase-1 inhibitor that has previously been shown to enhance the clinical response and overall patient survival when combined with CDDP by a yet unclear mechanism. We demonstrated that the combination of topotecan with CDDP significantly inhibited colony formation ability and increased the apoptosis of several cancer cell lines. Mechanistic analyses revealed that topotecan enhanced CDDP-induced DNA damage and inhibited the repair of DNA strand breaks, without affecting the cellular platinum content. Overall, the findings of this study demonstrated that the use of the FDA-approved drug panel in high-throughput screening is an effective method for identifying effective therapeutic regimens that are clinically relevant, and may have high feasibility for translation into clinical practice.

AB - cis-Diamminedichloroplatinum/cisplatin (CDDP) is a major drug used in cancer chemotherapy; however, the toxic side-effects and development of drug resistance represent major challenges to the clinical use of CDDP. The aim of the present study was to identify effective drug combination regimens through high-throughput drug screening that can enhance the efficacy of CDDP, and to investigate the underlying mechanisms. A cell-based high-throughput screening methodology was implemented, using a library of 1,280 Food and Drug Administration (FDA)-approved drugs, to identify clinical compounds that act synergistically with CDDP. Our study identified two compounds, namely potassium antimony tartrate and topotecan, that significantly enhanced the sensitivity of colorectal and non-small cell lung cancer cells to CDDP. The synergistic action of both compounds with CDDP was confirmed by further quantitative analyses. Topotecan is a topoisomerase-1 inhibitor that has previously been shown to enhance the clinical response and overall patient survival when combined with CDDP by a yet unclear mechanism. We demonstrated that the combination of topotecan with CDDP significantly inhibited colony formation ability and increased the apoptosis of several cancer cell lines. Mechanistic analyses revealed that topotecan enhanced CDDP-induced DNA damage and inhibited the repair of DNA strand breaks, without affecting the cellular platinum content. Overall, the findings of this study demonstrated that the use of the FDA-approved drug panel in high-throughput screening is an effective method for identifying effective therapeutic regimens that are clinically relevant, and may have high feasibility for translation into clinical practice.

KW - Cisplatin

KW - DNA damage

KW - Drug combination

KW - High-throughput screening

KW - PAT

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=85052018711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052018711&partnerID=8YFLogxK

U2 - 10.3892/ijo.2018.4447

DO - 10.3892/ijo.2018.4447

M3 - Article

C2 - 29956742

AN - SCOPUS:85052018711

VL - 53

SP - 1237

EP - 1246

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -